SFTPB
SFTPB (surfactant protein B, also known as SP-B or SFTP3) is an amphipathic pulmonary surfactant protein that lowers surface tension at the air-liquid interface of the lung's peripheral air spaces. It is essential for lung function and homeostasis after birth. Browse Assay Genie's current range of SFTPB research reagents below, or read on for the biology behind the target.
SFTPB encodes pulmonary surfactant-associated protein B, one of the proteins that promote alveolar stability by lowering surface tension at the air-liquid interface in the peripheral air spaces. Pulmonary surfactant is a surface-active lipoprotein complex of about 90% lipids and 10% proteins, the latter including SPA, SPB, SPC and SPD. SFTPB enhances the rate of spreading and increases the stability of surfactant monolayers in vitro, and it raises the collapse pressure of palmitic acid to nearly 70 millinewtons per meter.
The surfactant complex is secreted by the alveolar cells of the lung, where it coats the fluid lining and maintains the stability of pulmonary tissue. Within the cell and after release, the protein is found as a secreted product in the extracellular space, where it forms part of the surface film. The SFTPB gene belongs to the saposin B type domain containing group. Alternatively spliced transcript variants have been identified, and all of them encode the same protein. Mouse and rat both have an Sftpb ortholog.
The protein is also known as SP-B or SFTP3, and earlier HGNC nomenclature used the name surfactant, pulmonary-associated protein B. Multiple mutations in the SFTPB gene cause pulmonary surfactant metabolism dysfunction type 1, also called pulmonary alveolar proteinosis due to surfactant protein B deficiency. These mutations are associated with fatal respiratory distress in the neonatal period, which makes SFTPB a central protein in neonatal lung biology.
SFTPB lowers surface tension at the air-liquid interface and promotes alveolar stability, making it a core component for studying surfactant function.
Mutations in SFTPB are associated with fatal respiratory distress in the neonatal period, so the protein is relevant to neonatal lung disease research.
SFTPB mutations cause pulmonary surfactant metabolism dysfunction type 1, also called pulmonary alveolar proteinosis due to SP-B deficiency.
Surfactant is secreted by alveolar cells of the lung, and SFTPB is a useful protein for following this secretory product.
SFTPB, or surfactant protein B, helps promote alveolar stability by lowering surface tension at the air-liquid interface in the peripheral air spaces. It enhances the spreading rate and stability of surfactant monolayers in vitro and is essential for lung function and homeostasis after birth.
SFTPB is also called SP-B and SFTP3, and the NCBI Gene summary abbreviates it as SPB. Its former HGNC name was surfactant, pulmonary-associated protein B. UniProt lists the protein as pulmonary surfactant-associated protein B. Alternatively spliced transcripts all encode the same protein.
Yes. Multiple SFTPB mutations cause pulmonary surfactant metabolism dysfunction type 1, associated with fatal neonatal respiratory distress. Mouse and rat each have an Sftpb ortholog; check the datasheet of any product for its validated reactivity.
Other pulmonary surfactant proteins and lung-related targets that sit alongside SFTPB in surfactant research.
Gene and protein annotations from HGNC, NCBI Gene and UniProt P07988; product specifications from Assay Genie datasheets.